Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To determine 6 months progression-free survival of the combination of doxorubicin, cyclophosphamide and vindesine (VdsAC) plus valproic acid in patients with refractory SCLC after treatment with platinum derivatives, cisplatin or carboplatin, and etoposide.
Critère d'inclusion
- This is a prospective phase II study investigating well-known chemotherapeutic (doxorubicin, cyclophosphamide, vindesine) and antiepileptic (valproate) agents, in combination, for the treatment of refractory or recurrent small cell lung carcinoma after platinum derivatives and etoposide, for which no standard treatment is available in this indication